Mankind Pharma’s Q3 FY25 net profit declined 16% YoY to ₹385 crore despite a 24% revenue increase to ₹3,230 crore. Domestic revenues rose 17%, exports more than doubled, and consumer health grew 30%.
Positive Breakout: These 5 stocks cross above their 200 DMAs
In the Nifty200 pack, five stocks’ close prices crossed above their 200 DMA (Daily Moving Averages) on January 23, according to stockedge.com’s technical scan data.